Avicanna's CBG Products Reach 19 Countries: Denmark Joins Global Expansion
Avicanna's CBG Products Reach 19 Countries: Denmark Joins Global Expansion
CBG has been researched for potential therapeutic effects, including anti-inflammatory, antibacterial and neuroprotective benefits. It is also thought to be useful in treating conditions such as glaucoma and inflammatory bowel disease.Avicanna Inc. (OTC:AVCNF) biopharmaceutical company announced Thursday the successful export of its Aureus-branded cannabigerol (CBG) products to Denmark.
生物醫藥公司大麻股Avicanna Inc.（OTC:AVCNF）週四宣佈成功將其Aureus品牌的大麻二酚（CBG）產品出口到丹麥。這標誌着Aureus品牌產品在全球的市場達到了19個，Avicanna的產品總市場達到了22個。出口是通過Avicanna的大多數控股子公司Santa Marta Golden Hemp SAS實現的。
This marks the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna's product range. The export was facilitated through Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS.
這將成爲Avicanna的22個產品市場之一，其中Aureus品牌產品在19個國際市場上銷售。出口是通過Avicanna的大多數控股子公司Santa Marta Golden Hemp SAS實現的。
What Is CBG?
什麼是CBG？
Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the cannabis plant. Often referred to as the "mother cannabinoid," CBG is the precursor to other cannabinoids like THC and CBD. Specialized extraction methods can isolate CBG for its distinct properties.
大麻二酚（CBG）是大麻植物中的一種非精神活性大麻素。CBG通常被稱爲「母系大麻素」，是其他大麻素如THC和CBD的前體。通過特殊的提取方法，CBG可以被分離出來賦予其獨特的特性。
CBG has been researched for potential therapeutic effects, including anti-inflammatory, antibacterial and neuroprotective benefits. It is also thought to be useful in treating conditions such as glaucoma and inflammatory bowel disease.
研究表明CBG可能具有潛在治療效果，包括抗炎、抗菌和神經保護等益處。人們認爲它也有助於治療青光眼和炎症性腸病等疾病。
From Colombia To Denmark
從哥倫比亞到丹麥
Aureus products are developed in Santa Marta, Colombia, leveraging optimal environmental conditions to produce cannabinoid-active pharmaceutical ingredients (APIs) such as CBD, THC and CBG.
Aureus品牌產品是在哥倫比亞的Santa Marta研發的，利用最佳環保母基環境條件生產大麻活性藥物成分（API），如CBD、THC和CBG。
Avicanna reported these products are cultivated, extracted and manufactured by Avicanna's subsidiaries in Colombia, contributing to the company's supply chain for global distribution. The Aureus line supports Avicanna's cosmetic, medical and pharmaceutical product offerings.
Avicanna報告稱這些產品由Avicanna在哥倫比亞的子公司種植、提取和生產，爲全球分銷做出貢獻。Aureus系列支持Avicanna的化妝品、醫療和藥品產品。
Denmark's Cannabis Market
丹麥的大麻市場
Denmark's medicinal cannabis pilot program, launched on January 1, 2018, allows doctors to prescribe cannabis products previously illegal in the country. Running until December 31, 2025, the program aims to offer patients a legal alternative when other authorized medicines fail.
丹麥的醫用大麻試點計劃於2018年1月1日啓動，允許醫生處方此前在該國非法的大麻產品。該計劃運行時間爲至2025年12月31日，旨在爲患者提供合法替代品，當其他授權藥品無效時。
The cannabis products in the program are not traditional medicines. Consequently, doctors bear full responsibility for prescriptions, including determining dosages.
該計劃中的大麻產品並不是傳統藥品。因此，醫生承擔完全的處方責任，包括確定劑量。
The Danish government has issued guidelines for doctors, recommending medicinal cannabis primarily for conditions like multiple sclerosis-related spasms, chemotherapy-induced nausea, and specific neuropathic pain.
丹麥政府已發佈指南，推薦醫用大麻主要用於治療多發性硬化相關痙攣、化療引起的噁心和特定的神經疼痛。
These issues will be among the hot topics at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the industry. Hear directly from top executives, investors, advocates, and policymakers. Get your tickets now before prices go up by following this link.
這些問題將是即將到來的芝加哥Benzinga大麻資本會議的熱門話題，時間是10月8日至9日。加入我們，以獲取關於大麻合法化浪潮對該行業投資未來意味着什麼的更深入了解。直接聽取高管，投資者，倡導者和政策制定者的意見。在通過此鏈接購買門票之前，抓緊時間，因爲價格會上漲。
Photo: AI-generated image.
照片：人工智能生成的圖像。
譯文內容由第三人軟體翻譯。
